

The prevalence and immunological features of anti-glomerular basement membrane antibody in patients with HIV

Wenjing Wang

Capital Medical University

Xiao-yu Jia Jia

Peking University First Hospital

Zhao Cui

Peking University First Hospital

Yan Chen

Capital Medical University

Wei Wang

Capital Medical University

Jin-li Lou

Beijing youan hospital

Ming-hui Zhao

Peking University First Hospital

Sun Ying (✉ ying.sun@ccmu.edu.cn)

Research article

Keywords: Anti-GBM antibodies; Antigen; IgG subclasses; HIV; AIDS;

DOI: <https://doi.org/10.21203/rs.2.21447/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Anti-glomerular basement membrane disease (GBM) is a kind of chronic autoimmune disease caused by the deposition of circulating anti-GBM antibodies. Non-collagen region of $\alpha 3$ chain of type IV collagen ($\alpha 3(\text{IV})\text{NC1}$) is one of the main target antigens. And on $\alpha 3$, E_A and E_B are the most classical antigen epitopes. It has been reported that anti-GBM antibodies can be detected in HIV patients, but its immunological characteristics are still unclear. In this study, the immunological characteristics of the target antigens were clarified.

Methods: Total 93 HIV patients and 20 healthy volunteers were selected in Beijing Youan Hospital from 2017 to 2018. Recombinant human $\alpha 1$ - $\alpha 5(\text{IV})\text{NC1}$, chimeric protein E_A and E_B were used as solid phase antigens. Enzyme-linked immunosorbent assay was employed to measure concentrations and subtypes of serum IgG autoantibodies specifically against GBM.

Results: Five out of the 93 patients with HIV had low to moderate levels of anti-GBM antibodies. However, these patients presented with no clinical manifestation of any kidney injury or pulmonary hemorrhages. Compared with HIV patients with negative antibodies, there were no significant differences in gender, age, $\text{CD4}^+\text{T}$ cell count and HIV viral load. All sera of five patients recognized non-collagenous domain1 (NC1) of alpha 3 chain of type IV collagen [$\alpha 3(\text{IV})\text{NC1}$] as classic anti-GBM patients, followed by $\alpha 5(\text{IV})\text{NC1}$. The antibodies against $\alpha 3(\text{IV})\text{NC1}$ were IgG3 predominant, but did not react with either of the classic epitopes on $\alpha 3$ (E_A and E_B).

Conclusion: These data suggest a distinct immunological profile of anti-GBM antibodies in patients with HIV, and might explain the non-pathogenic features of HIV associated anti-GBM antibodies.

Background

The acquired immunodeficiency syndrome (AIDS), first discovered in the 1980s, is a kind of infectious disease caused by the human immunodeficiency virus (HIV). It can cause acquired immunodeficiency in humans, leading to various infections, and malignant tumors, while end-stage patients may suffer from multiple organ dysfunction and death. Some studies have shown that 30% among them may have abnormal renal functions, and those kidney damage in HIV-infected patients manifests in a variety of ways, including acute kidney injury (AKI), HIV-associated kidney disease, comorbid chronic kidney disease (CKD) and treatment-related kidney toxicity [1-3].

Many kinds of autoantibodies can be detected in HIV infected patients, including anti-nuclear (ANA), anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) antibodies[4]. Anti-GBM antibodies are pathogenic of the anti-GBM disease, and this disease often manifests as the aggressive crescentic glomerulonephritis[3]. The target antigen of this antibody is the non-collagenous domain1 (NC1) of alpha 3 chain of type IV collagen ($\alpha 3(\text{IV})\text{NC1}$), which normally expresses in the glomerular and alveolar basement membranes[1]. However, in most of the cases with anti-GBM antibodies detected in HIV patients, there were no obvious clinical manifestations of renal damage[5, 6]. It is still in controversy whether these antibodies are pathogenic as the ones in classic anti-GBM patients. In the present study, therefore, we measured the anti-GBM antibodies in the serum of HIV patients and analyzed, for the first time to our best knowledge, the immunological characteristics of these antibodies in order to provide some clues.

Methods

Subjects and sera

Ninety-three patients with HIV, diagnosed in Beijing Youan Hospital from January to December in 2018, were enrolled in the present study. The diagnosis of patients was based on the relevant provisions of WHO and China's national industry standards[7]. According to the diagnostic criteria, all patients were diagnosed as the asymptomatic stage or AIDS since blood samples from patients with acute infection are difficult to collect. Patients with kidney injury caused by other causes, including recent severe trauma or surgery, and non-AIDS related acute and chronic infectious diseases, children, pregnant or lactating women and patients who did not meet the ethical requirements of informed consent were excluded. Sera of positive control were obtained from patients with classical anti-GBM disease diagnosed in Peking University First Hospital. Normal human sera were obtained from 20 healthy volunteers from Beijing Youan Hospital.

All serum samples were collected and stored at $-80\text{ }^\circ\text{C}$ until use. Clinical data of HIV patients were collected at the time of diagnosis and during follow-up. Siemens Advia2400 automatic biochemical analyzer was employed for renal function test, among which creatinine was measured by enzyme method, urea was measured by Urease method, and glomerular filtration rate was calculated by simplified MDRD formula. Sysmex XN series and relevant reagents were used for blood routine test (e.g. Hemoglobin), while Arkary AX4030 and necessary reagents were used for urine routine test (such as protein, red blood cell, etc.). BD FACS Canto II flow cytometer and the matching reagents were used for CD4 count, while Abbott real-time HIV-1 reagents were used for HIV viral load determination. The present study was in compliance of the Declaration of Helsinki and approved by the ethics committee of Beijing Youan Hospital and Peking University First Hospital. Informed consent was obtained from each individual.

Preparation of recombinant human $\alpha(\text{IV})\text{NC1}$ and chimeric proteins

The recombinant human α (IV)NC1 and chimeric protein were prepared as follows. Briefly, the cDNAs of the α 1- α 5(IV)NC1 were ligated into the X-type collagen triple helix guide sequence and cloned into the pcDNA plasmid. Then the plasmid was transfected into human embryonic kidney 293 cell line, and recombinant proteins were harvested from the culture solution after purification[8].

The construct E_A and E_B consists entirely of the α 1(IV)NC1 domain, E_A contain 45 amino acids of α 3(IV)NC1 E_A region, and E_B contain 37 amino acids of α 3(IV)NC1 E_B region. Construction of non- E_{AB} was constructed in the context of α 3(IV)NC1, in which the E_A and E_B regions were replaced by the corresponding amino acids of α 1(IV)NC1[8, 9].

Detection of anti-GBM antibodies in serum samples using enzyme-linked immunosorbent assay

A home-based enzyme-linked immunosorbent assay (ELISA) was performed to measure anti-GBM antibodies in the sera. In brief, a mixture of the recombinant human α 1- α 5(IV)NC1 proteins was diluted with carbonate buffer solution (CBS 0.05 M, pH 9.6) to the concentration of 1.0 μ g/mL for each antigen, and coated onto half of the wells of the polystyrene microtiter plate (Nunc, Roskilde, Denmark). The other half of the wells was coated with bovine serum albumin (BSA) as antigen-free wells, and they were diluted at the same concentration in 0.05M CBS to exclude non-specific binding. Incubation at 37°C for 60 min. After washing, the serum samples (1:100 diluted with a dilution buffer containing 0.64 M NaCl, 0.008 M Na₂HPO₄·12H₂O, 0.003 M KCl, 0.002 M KH₂PO₄, 0.1% Tween-20, pH 7.4) were then added to the antigen coated and antigen-free wells respectively. Incubation again at 37°C for 60 min. After washing, alkaline phosphatase-conjugated goat anti-human IgG (Fc specific, Sigma, USA, 1:6000) was added, and incubation again at 37°C for 60 min. After washing, 50 μ L of substrate solution (containing 1 mg/mL p-nitrophenyl phosphate, 1.0 M diethanolamine, 0.5 M MgCl₂, pH 9.8, Sigma, USA) was added into the wells for color development which was measured spectrophotometrically at 405 nm (Bio-Rad, Tokyo, Japan) 15min later. The net absorbance values were OD values of the antigen-coated wells minus the OD values of the antigen-free wells. Each serum sample was tested in duplication, while the samples were re-tested when the standard deviation between the wells >10%. Serum samples from healthy volunteers were used to build up the cutoff values using mean+2 SD for mixture α chains and the chimeric proteins.

Detection of antigen and epitope specificity in sera of HIV patients with anti-GBM antibodies

To detect antigen and epitope specificity, plate wells were respectively pre-coated with each of the five-recombinant human α (IV)NC1 or the chimeric proteins containing E_A , E_B and non- E_{AB} (1 μ g/mL per protein). Serum samples of HIV patients with anti-GBM antibodies were diluted at 1:50 and added in duplication into the wells at 37°C for 60 min. After washing, alkaline phosphatase-conjugated goat anti-human IgG (Fc specific, Sigma, USA) was added, and incubation at 37°C for 60 min. Color was developed and measured as described above. Serum samples from healthy volunteers were used to build up the cutoff values using mean+2 SD for each α chain and the chimeric protein.

Detection of distribution of IgG subclass against α 3(IV)NC1 in HIV patients with anti-GBM antibodies

The detection of IgG subclasses against α 3(IV)NC1 was performed as previously reported[8]. In brief, the recombinant human α 3(IV)NC1 proteins were diluted at 1 μ g/mL and coated onto half of the wells of a polystyrene microtiter plate. The other half of the wells was coated with BSA as antigen-free wells. Diluted serum samples at 1:100 were then added to the antigen and BSA coated wells respectively, and incubated at 37°C for 60 min. After washing, horseradish peroxidase labeled mouse monoclonal antibodies against human IgG1, IgG2, IgG3, and IgG4 (Fc specific, Southern Biotech, USA, 1:2000) were added at 37°C for 60 min. After washing, color was developed by adding 50 μ L of substrate (Tetramethyl benzidine, TMB, Invitrogen, USA) into the wells for 15 min. Reaction was terminated by adding stop solution and color measured at 450 nm. Again, serum samples from healthy volunteers were used to build up the cutoff values using mean+2 SD at the same steps.

Quality Control

All laboratory test indexes were monitored by quality control materials with at least two levels. In the routine urine analysis, in case of positive alarm of red blood cells, white blood cells, proteins and nitrites, artificial microscopy was employed to eliminate the interference of false positive (such as mucous filaments).

Statistics

Continuous variables were expressed as means \pm SD or medians. Comparison between continuous variables was conducted by *t* test for normally distributing data or nonparametric test for non-normally distributing data. Differences between qualitative data were analyzed using χ^2 or Fisher exact test. All statistical analyses were two-tailed and *P* <0.05 was considered significant different. Analysis was performed using the IBM SPSS statistics 24.0 software.

Results

The Demographic and Clinical data of patients with HIV

A consecutive of 93 patients diagnosed with HIV from January to December in 2018 was enrolled in the present study, including 73 males and 20 females with a mean age of 36 years. Among these subjects, 48/93 (51.6%) patients were asymptomatic while the remaining were at the stage of AIDS. 32 (34.4%) of all the patients had a history of infections, including pulmonary, blood or other tissues, and 20 (21.5%) of them had laboratory evidence (supported by bacterial culture or molecular diagnosis). 16 (17.2%) patients had urinary protein (protein appeared in urine, and semi quantitative analysis > 0.3g/L). All patients received anti-viral therapies and were followed up for a median time of 6 months. Two (2/93, 2.15%) patients died from pulmonary infection and multi-organ failure during their hospitalization, while 3 (3/93, 3.23%) were lost at the end of follow-up. The demographic and clinical data are shown in Table 1.

The prevalence of circulating anti-GBM antibodies in patients with HIV

Serum samples of 20 normal controls were collected and used to build up the cutoff values of anti-GBM antibodies. The mean OD values of healthy controls was 0.050 ± 0.110 , and cutoff value was 0.270. A total of 5 sera (5.37%) from the 93 patients showed reactivity against a mixture of all five human α (IV)NC1 chains. Among them, 4 were male and one female, with a mean age of 39.8 ± 11.3 years.

None of these 5 patients with anti-GBM antibodies had hemoptysis or any kind of kidney injuries including urinary protein or hematuria. However, these 5 patients presented significantly higher levels of serum urea (5.3 ± 0.6 vs. 4.2 ± 1.2 mmol/L, $p = 0.027$), creatinine (78.5 ± 25.1 vs. 59.7 ± 15.8 μ mol/L, $p=0.014$) and lower levels of estimated glomerular filtration rate (eGFR, 103.2 ± 24.1 vs. 121.7 ± 19.9 ml/min/1.73m², $p=0.048$), compared with the AIDS/HIV patients without the antibodies. In HIV patients without anti-GBM antibodies, urinalysis indicated urinary protein (mostly 1+) in 16 cases (18.8%, 16/88) and hematuria (mostly 1+) in 3 cases (3.41%, 3/88), respectively.

There were no significant differences in HIV viral load and CD4⁺ T lymphocyte count between HIV patients with or without anti-GBM antibodies (Table 2). However, the prevalence of infections in patients with anti-GBM antibodies seemed to be higher than those of patients without anti-GBM antibodies. Three out of the 5 patients (60%, 3/5) possessing anti-GBM antibodies had bacterial infections, compared to the corresponding figure of 11/88 (12.5%) in anti-GBM negative patients ($P=0.004$). No matter either CD4⁺ T cell count less than 200/ μ L or 400/ μ L was used as a marker of immune deficiency, there were no differences in the renal function and the prevalence of the anti-GBM antibodies between groups (Table 3).

However, the prevalence of infections in patients with anti-GBM antibodies seemed to be higher. Three out of the 5 patients (60%, 3/5) possessing anti-GBM antibodies had infections, compared to the corresponding figure of 17/88 (19.3%) in anti-GBM negative patients ($P=0.031$).

All patients involved the study had received free antiviral treatment (used Lamivudine/Zidovudine, Tenofovir fumarate, Lopinavir, Eferene or Latiravir), including the patients with anti-GBM antibodies (treated with Lamivudine, Tenofovir fumarate or Eferene). There were no differences in urine protein, serum creatinine, urea and eGFR among the three drugs.

Antigens and epitope specificity of anti-GBM antibodies in the sera of HIV patients

The recombinant human $\alpha 1$ to $\alpha 5$ (IV)NC1 were used to determine antigen specificity of anti-GBM antibodies. Among these 5 patients, one failed to react with either of the five α chains. Sera of the remaining four patients (4/4, 100%) all recognized $\alpha 3$ (IV)NC1, while 2 sera (2/2, 50%) recognized $\alpha 5$ (IV)NC1. Only one patient (1/5, 20%) reacted with $\alpha 1$ (IV)NC1, $\alpha 2$ (IV)NC1, $\alpha 4$ (IV)NC1 (Table 4). Sera from positive controls recognized both E_A and E_B. However, none of the three chimeric proteins was recognized by the sera from the 4 HIV patients with anti- $\alpha 3$ (IV)NC1 antibodies (Table 4).

IgG subclass distribution of serum antibodies against $\alpha 3$ (IV)NC1

IgG subclasses were further detected in the 4 HIV patients with anti- $\alpha 3$ (IV)NC1 antibodies. Among them, IgG3 was the dominant subtype (100%, 4/4), while IgG1 and IgG4 were detected in 1/4 case, respectively. IgG2 subclass was not detected in any sera (Table 5).

Follow up of HIV patients with anti-GBM antibodies

All the 5 patients possessing anti-GBM antibodies were followed up for 6-12 months (Table 6). Among them, 2 patients showed slight decline of eGFR (decreased by 10.4% and 11.4% respectively). One patient, whose serum recognized all five α chains, developed elevated level of urinary protein (semi-quantitative detection at 1.0g/L). The remaining 3 patients showed no renal impairment.

Discussion

Kidney dysfunction caused by HIV infection is related to a number of reasons including the course of disease, viral load status, drug treatments, co-infections, tumorigenesis and metabolic disorders[10, 11]. It has been reported that HIV patients have autoantibodies against GBM, complicating the dissection of the causes for kidney involvement[4]. Although classic anti-GBM antibodies are recognized to be pathogenic, most HIV cases with anti-GBM antibodies manifest no features of anti-GBM nephritis[4, 5]. In order to further elucidate the pathogenesis of these antibodies, we investigated, for the first time to our best knowledge, the immunological characteristics of the anti-GBM antibodies in HIV patients and their associations with clinical data.

A total of 5 out of 93 HIV patients were found to possess low to moderate levels of anti-GBM antibodies. However, no kidney injury or hemoptysis was found in the 5 patients at the time of testing. Therefore, these antibodies in HIV patients seem to be non-pathogenic, as consistent with previous reports[5, 6]. Because there were no differences in the concentrations of serum creatinine of patients with any of the antiviral drug treatment, this suggested that these antiviral drugs did not cause renal damage in these patients yet, at least at the time of the study. It has been reported that the production of anti-GBM antibody is related to CD4⁺ T cell count, in which the authors found a significant correlation between the presence of anti-GBM antibodies and CD4 counts less than 400/mL[4]. However, we didn't find such tendency, even though CD4 count less than 200/mL was used as a marker of severe immunodeficiency, therefore, the relationships between CD4⁺ T cell count and autoantibody production in HIV patients still need to be further clarified.

Among the patients, one patient failed to react with any of the five-alpha chain, which is probably due to the low reactivity of the antibodies to each alpha chain, though the total IgG bound to all the five alpha chains could be detected. In the present study, one of the 5 anti-GBM positive patients, who had the antibodies against all 5 α chains, also had a high viral load, suggesting that the CD4⁺ T cell count might associate with HIV viral load in the point of view of antigenic reorganization. However, we did not find significant difference in CD4⁺ T cell count and HIV viral load between HIV patients with or without the antibodies, probably because all patients in our study had taken antiviral drugs. Furthermore, our data revealed that the prevalence of anti-GBM antibodies were associated with bacterial infections. Previous studies have shown that *P. carinii* alveolar injury or the host response to the organism might affect the Goodpasture antigen or a similar antigen, because Goodpasture's syndrome could be triggered by an alveolar lesion induced by *P. carinii* pneumonia[5, 12]. Anti-GBM disease associated with other infections including dengue virus has also been reported[13]. Taken together, these suggest that there might be an important link between infection and the emergency of anti-GBM antibodies, which needs to be further investigated.

Although the production of autoantibodies associated with HIV infections are thought to be caused by poly-clonal activation of CD4⁺ T cells, we found that anti-GBM antibodies in HIV patients were rather specific and recognized a relatively narrower antigen spectrum. Almost all sera recognized $\alpha 3(\text{IV})\text{NC1}$ and half of them reacted with $\alpha 5(\text{IV})\text{NC1}$, while the recognition of other α chains were limited. It has been shown that the main target antigen recognized by GBM antibody is $\alpha 3(\text{IV})\text{NC1}$, and that the level of $\alpha 3(\text{IV})\text{NC1}$ antibody is a key factor in the extent of kidney damage in classic anti-GBM diseases[14, 15]. Recently, antibodies against $\alpha 5(\text{IV})\text{NC1}$ has been proved to be pathogenic in Goodpasture's disease as well[16]. However, in the present study, none of these HIV/AIDS patients with anti-GBM antibodies had clinical evidence of renal injuries. It is of notice that most of the anti-GBM antibodies in these patients were borderline positive, with only one patient possessing moderately elevated level of antibodies against $\alpha 3(\text{IV})\text{NC1}$. Moreover, none of these sera recognized the two major epitopes on $\alpha 3(\text{IV})\text{NC1}$, namely E_A and E_B. It has been shown that patients with high levels of circulating antibodies against the specific epitopes E_A and E_B have a more severe renal disease at diagnosis as well as a worse prognosis[17]. Data derived from animal models suggest a non-pathogenic but augmenting effect of anti-EB antibodies in the development of crescentic glomerulonephritis[18]. Some other studies have demonstrated that in human anti-GBM disease the levels of anti-E_B antibodies are positively associated with severity of renal damage[17]. Therefore, we speculate that the antibodies in these patients might recognize non-pathogenic epitopes on $\alpha 3$ and $\alpha 5(\text{IV})\text{NC1}$, therefore exerting no kidney injuries.

Savige et al. have shown that plasma samples from 18 of 105 HIV infected individuals are positive for anti-GBM antibodies. Most of the patients also have borderline levels of anti-GBM antibodies, though the prevalence is much higher than those involved in the present study. The authors suggest that these antibodies may arise from polyclonal activation, or be due to "sticky" serum[4], especially when sera diluted at 1:8. In the present study, all serum samples were diluted at 1:100 to reduce false positivity, which might be one of the reasons for a lower prevalence of anti-GBM antibodies in our study.

Limitations

There are certain limitations in the present study. For example, the sample size is small, while the research time is still short. Furthermore, it is difficult to determine the specific time of HIV infection for each individual patient. In fact, many patients were only found in the occasional physical examination, and some patients went to the hospital for examination when they had other clinical symptoms. In this case, it is hard to know the exact time when the patients were actually infected with HIV virus. Also, the epitope peptide corresponding to the positive sample has not been found, which will need to pay more attention in the future work.

Conclusions

Five out of 93 HIV patients were found to have low to moderate levels of anti-GBM antibodies. However, none of the patients manifested any kind of kidney injuries or pulmonary hemorrhages. These antibodies recognized a specific and narrow antigen spectrum encoding $\alpha 3$ and $\alpha 5(\text{IV})\text{NC1}$, but had a distinct epitope repertoire. The differences in immunological characteristics may explain the non-pathogenic features of HIV associated anti-GBM antibodies.

Abbreviations

HIV: Human immunodeficiency virus; GBM: Glomerular basement membrane disease; AIDS: Acquired immunodeficiency syndrome; AKI: Acute kidney injury; CKD: Comorbid chronic kidney disease; ANA: Anti-nuclear antibody; ANCA: Anti-neutrophil cytoplasmic antibody; NC1: Non-collagenous domain1; $\alpha 3(\text{IV})\text{NC1}:\text{NC1}$ of alpha 3 chain of type IV collagen; Ig: Immunoglobulin; WHO: World Health Organization; MDRD: The Modification of Diet in Renal Disease equation; CD: Cluster of Differentiation; CBS: Carbonate Buffer solution; OD: Optical density; SD: Standard Deviation; UPRO: Urine Protein; UREA: serum urea; CRE: serum creatinine; eGFR: estimated glomerular filtration rate; TND: target not detected.

Declarations

Ethics approval and consent to participate

Ethical approval for the study was granted by the Ethics Committee of Beijing You'an hospital. As a result of the retrospective design of the study and the corresponding policy, the local ethics committee confirmed that the conditions for exemption from informed consent were met and that participants were not required to give informed consent.

Consent for publication

Not applicable.

Availability of data and materials

Our database contains sensitive data, which can provide clinical data and personnel information about our patients and lead to the identification of these patients. Therefore, according to the restrictions and provisions of the relevant organizations, these data cannot be publicly provided. However, if the requirements are reasonable, datasets used and/or analyzed in this study can be obtained from the authors.

Competing interests

All of the authors read and approved the final manuscript. All of the authors declare that they have no competing interests.

Funding

This work was supported by grants of the National Natural Science Fund of China to the Innovation Research Group (81621092), the Outstanding Young Scholar (81622009), and other programs (81330020, 81370801, 81870482).

Authors' contributions

XYJ and ZC were responsible for the study design. WJW, JLL were responsible for data collection, specimen collection and experiments; WJW, XYJ and ZC were analyzed and interpreted the data; WJW, XYJ drafted the manuscript; WJW, XYJ, ZC, YC, WW, JLL, MHZ and SY critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We sincerely thank Miao Wang who gave the technical support.

Author details

1 Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.

2 Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

3 Renal Division, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China; Beijing 100034, China

4 Peking-Tsinghua Center for Life Sciences, Beijing 100871, China

References

1. Ray PE: **HIV-associated nephropathy: a diagnosis in evolution.** *Nephrol Dial Transplant* 2012, **27**(11):3969-3972.doi:10.1093/ndt/gfs114.
2. Jotwani V, Atta MG, Estrella MM: **Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.** *J Am Soc Nephrol* 2017, **28**(11):3142-3154.doi:10.1681/ASN.2017040468.
3. Wyatt CM: **Kidney Disease and HIV Infection.** *Top Antivir Med* 2017, **25**(1):13-16
4. Savige JA, Chang L, Horn S, Crowe SM: **Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals.** *Autoimmunity* 1994, **18**(3):205-211.doi:10.3109/08916939409007997.

5. Szczech LA, Anderson A, Ramers C, Engeman J, Ellis M, Butterly D, Howell DN: **The uncertain significance of anti-glomerular basement membrane antibody among HIV-infected persons with kidney disease.** *Am J Kidney Dis* 2006, **48**(4):e55-59.doi:10.1053/j.ajkd.2006.06.007.
6. Minocha V, Makary R, Poenariu A: **An Unusual Case of Anti-GBM Antibody Elevation in HIV-Associated Nephropathy.** *Case Rep Nephrol* 2014, **2014**:956475.doi:10.1155/2014/956475.
7. World Health Organization: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2016
8. Jia XY, Hu SY, Chen JL, Qu Z, Liu G, Cui Z, Zhao MH: **The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy.** *Kidney Int* 2014, **85**(4):945-952.doi:10.1038/ki.2013.364.
9. Netzer KO, Leinonen A, Boutaud A, Borza DB, Todd P, Gunwar S, Langeveld JP, Hudson BG: **The goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain.** *J Biol Chem* 1999, **274**(16):11267-11274.doi:10.1074/jbc.274.16.11267.
10. Szczech LA: **Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management.** *Clin Infect Dis* 2001, **33**(1):115-119.doi:10.1086/320893.
11. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE *et al.* **The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.** *Kidney Int* 2004, **66**(3):1145-1152.doi:10.1111/j.1523-1755.2004.00865.x.
12. Calderon EJ, Wichmann I, Varela JM, Respaldiza N, Regordan C, Fernandez-Alonso J, Medrano FJ, Cano S, Cuello JA, Nunez-Roldan A: **Presence of glomerular basement membrane (GBM) antibodies in HIV- patients with Pneumocystis carinii pneumonia.** *Clin Exp Immunol* 1997, **107**(3):448-450.doi:10.1046/j.1365-2249.1997.d01-969.x.
13. Lizarraga KJ, Florindez JA, Daftarian P, Andrews DM, Ortega LM, Mendoza JM, Contreras GN, Nayer A: **Anti-GBM disease and ANCA during dengue infection.** *Clin Nephrol* 2015, **83**(2):104-110.doi:10.5414/CN108217.
14. Kalluri R, Wilson CB, Weber M, Gunwar S, Chonko AM, Neilson EG, Hudson BG: **Identification of the Alpha-3 Chain of Type-Iv Collagen as the Common Autoantigen in Antibasement Membrane Disease and Goodpasture-Syndrome.** *Journal of the American Society of Nephrology* 1995, **6**(4):1178-1185
15. Dehan P, Weber M, Zhang X, Reeders ST, Foidart JM, Tryggvason K: **Sera from patients with anti-GBM nephritis including goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen alpha chains.** *Nephrol Dial Transplant* 1996, **11**(11):2215-2222.doi:10.1093/oxfordjournals.ndt.a027139.
16. Cui Z, Zhao MH, Jia XY, Wang M, Hu SY, Wang SX, Yu F, Brown KL, Hudson BG, Pedchenko V: **Antibodies to alpha5 chain of collagen IV are pathogenic in Goodpasture's disease.** *J Autoimmun* 2016, **70**:1-11.doi:10.1016/j.jaut.2016.04.001.
17. Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, Wang HY: **Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease.** *Nephrol Dial Transplant* 2009, **24**(6):1838-1844.doi:10.1093/ndt/gfn761.
18. Chen L, Hellmark T, Wieslander J, Bolton WK: **Immunodominant epitopes of alpha3(IV)NC1 induce autoimmune glomerulonephritis in rats.** *Kidney Int* 2003, **64**(6):2108-2120.doi:10.1046/j.1523-1755.2003.00332.x.

Tables

Table 1. The Demographic and Clinical data of patients with HIV

Parameters	n=93
Age (years)	36.1±10.7
Gender (male/female)	73/20
Stage (Asymptomatic/AIDS)	45/48
CD4 ⁺ T cell count (/mL) (median, range)	292 (0-1734)
HIV load (copies /mL) (median, range)	0 (0-3257132)
Infections (n, %)	20, 21.5%
Hemoglobin (g/L)	126.6±30.8
Serum urea (mmol/L)	4.2±1.2
Serum creatinine (μmol/L)	60.8±16.7
eGFR (ml/min/1.73m ²)	120.8±20.3
Urinary protein (n, %)	16, 17.2%

Table 2. Comparison of clinical features of HIV patients with and without anti-GBM antibodies

Parameters	with anti-GBM antibodies (n=5)	without anti-GBM antibodies (n=88)	P value
Age (years)	36.6±9.8	36.3±11.0	0.939
Gender (male/female)	4/1	69/19	0.933
Stage (Asymptomatic/AIDS)	4/1	44/44	0.192
CD4 ⁺ T cell count (/mL)	520.6±171.6	146.8±214.0	0.308
CD4/CD8 ratio	0.77±0.62	0.07±0.05	0.235
HIV Load (Detected/NOT)	1/4	29/59	0.052
Antiviral drug (Lamivudine/ Tenofovir fumarate/ Eferene)	5/4/5	64/53/46	0.873
Hemoglobin (g/L)	141.0±32.1	125.8±30.7	0.284
Serum urea (mmol/L)	5.3±0.6	4.2±1.2	0.027*
Serum creatinine (µmol/L)	78.5±25.1	59.8±15.7	0.014*
eGFR (ml/min/1.73m ²)	103.2±24.1	121.8±19.8	0.046*
Infections (n, %)	3, 60%	17, 19.3%	0.031*
Urinary protein n, %	0	16, 18.2%	0.295

*P<0.05

Table 3. Comparison of anti-GBM antibody level and renal function in CD4 count

CD4 ⁺ T cell count (/mL)	>200 N=58			>400 N=37			*P<0.05
	<200 (N=35)	P	<400 (N=56)	P			
N _{GBM(+)}	1	0.34	1	0.34			
OD _{GBM level}	0.06±0.07	0.06	0.05±0.07	0.06			
Serum urea (mmol/L)	4.2±1.0	0.71	4.3±1.2	0.67			
Serum creatinine (µmol/L)	62.0±20.0	0.57	60.2±17.7	0.69			
eGFR (ml/min/1.73m ²)	121.9±29.6	0.68	122.2±24.7	0.40			

Table 4. Target antigens of circulating anti-GBM antibodies in HIV patients

	Antigen distribution					Epitope on α3(IV)NC1		
	α1(IV)NC1	α2(IV)NC1	α3(IV)NC1	α4(IV)NC1	α5(IV)NC1	E _A	E _B	Non-E _{AB}
P1	0.050	-0.051	-0.024	-0.04	-0.043	-	-	-
P2	0.155 ^Δ	0.612 ^Δ	0.324 ^Δ	0.079 ^Δ	0.095 ^Δ	0.026	-0.016	0.028
P3	0.039	0.031	0.142 ^Δ	-0.086	0.131 ^Δ	-0.006	0.009	0.011
P4	0.001	0.015	0.138 ^Δ	-0.001	0.024	0.005	0.066	0.151
P5	0.031	-0.003	0.132 ^Δ	0.005	0.011	0.043	0.037	0.067
Normal controls	0.017±0.034	0.037±0.070	0.012±0.027	-0.036±0.051	0.009±0.028	0.052±0.049	0.036±0.060	0.078±0.064
Cut-off value	0.085	0.178	0.066	0.067	0.066	0.150	0.156	0.205

itive OD value

Table 5. IgG subclass distribution of circulating antibodies against α3(IV)NC1 in HIV patients

	IgG subclass distribution			
	IgG1	IgG2	IgG3	IgG4
P1	-	-	-	-
P2	-0.07	-0.002	0.196 ^Δ	0.004
P3	0.078	0.005	0.138 ^Δ	-0.015
P4	0.133	-0.003	0.252 ^Δ	0.281 ^Δ
P5	0.225 ^Δ	0.007	0.136 ^Δ	-0.137
Normal controls	0.067±0.048	-0.003±0.017	-0.010±0.029	-0.010±0.054
Cutoff value	0.163	0.031	0.048	0.098
cut-off value	0.085	0.178	0.066	0.067

itive OD value

Table 6. Clinical data of anti-GBM-positive HIV patients during follow-up

No	Gender	Stage	on the time of testing						follow-up after one year								
			CD4	Viral load	UPRO	UREA	CRE	eGFR	CD4	Viral load	UPRO	UREA	CRE	eGFR			
			(/μL)	(copy/ml)		(mmol/L)	(μmol/L)	(ml/min/1.73m ²)				(/μL)	(copy/ml)		(mmol/L)	(μmol/L)	(ml/min/1.73m ²)
P1	Male	AIDS stage	42	TND	-	6.4	109.3	69.1	58	TND	-	4.2	84.8	86.9			
P2	Male	Asymptomatic	407	791856	-	5.4	74.0	124.5	451	42	2+	5.0	84.5	111.6			
P3	Male	Asymptomatic	440	<40	-	4.9	67.1	119.1	460	TND	-	6.2	73.1	114.2			
P4	Male	Asymptomatic	776	TND	-	5.2	96.5	86.7	608	TND	-	5.2	106.9	76.8			
P5	Female	Asymptomatic	459	TND	-	5.0	45.4	116.7	645	TND	-	5.6	51.9	110.8			